Three decades after its development, ready-to-use therapeutic food (RUTF) has transformed treatment for severe acute malnutrition, saving an estimated 7 million children’s lives. However, according to UNICEF’s latest analysis, 45 million children under five still require this life-saving intervention but lack access to treatment.
Global Severe Acute Malnutrition Treatment Gap
Children requiring RUTF treatment vs. those receiving it, 2024
treatment
RUTF
to treatment
Source: UNICEF, 2024 | Georgian Medical Journal News
Three Decades of Innovation Transform Child Survival
Ready-to-use therapeutic food emerged in the 1990s as a revolutionary approach to treating severe acute malnutrition in children. The World Health Organization defines severe acute malnutrition as a condition affecting children whose weight-for-height is below -3 standard deviations of the median, or who have visible severe wasting.
RUTF consists of a nutrient-dense paste containing peanuts, milk powder, oil, sugar, and essential vitamins and minerals. Unlike previous hospital-based treatments, RUTF can be administered at home by caregivers, dramatically expanding access to life-saving care in resource-limited settings.
Treatment Gap Persists Despite Proven Efficacy
Despite three decades of success, significant barriers prevent millions of children from accessing RUTF treatment. UNICEF data indicate that only 5 million of the 45 million children requiring treatment currently receive it, representing an 89% treatment gap.
The highest burden of severe acute malnutrition remains concentrated in sub-Saharan Africa and South Asia, where conflict, climate change, and economic instability compound access challenges. Supply chain disruptions and limited healthcare infrastructure further restrict RUTF distribution to remote communities.
For more insights on global health initiatives addressing malnutrition, visit our Global Health section.
Economic and Operational Barriers Limit Scale-Up
Cost remains a significant barrier to RUTF access, with treatment courses ranging from $40 to $200 per child depending on the duration and severity of malnutrition. Production capacity constraints also limit availability, as most RUTF manufacturing occurs in high-income countries rather than regions with the greatest need.
Local production initiatives have emerged in several African countries, but regulatory frameworks and quality assurance systems require strengthening to ensure product safety and efficacy. The FDA’s regulatory guidance provides frameworks that could be adapted for international RUTF production standards.
Innovation Pipeline Offers Hope for Expanded Access
Recent developments in RUTF formulation and delivery mechanisms show promise for addressing current gaps. Alternative protein sources and locally-sourced ingredients are being tested to reduce costs and improve cultural acceptability.
Digital health platforms are also being deployed to improve case detection and treatment monitoring in remote areas. These innovations, combined with increased funding commitments from donor governments, could significantly expand RUTF access over the next decade.
For updates on nutrition research and policy developments, explore our Health Policy coverage.
RUTF has achieved cure rates of 85-90% when properly administered, making it one of the most effective interventions for preventing child mortality in humanitarian settings.
— UNICEF Nutrition Programme Analysis, 2024
Key takeaways
- 7 million children’s lives have been saved through RUTF treatment over 30 years
- 89% treatment gap persists, with 40 million children lacking access to needed care
- Local production and digital health innovations could dramatically expand access
Frequently asked questions
What is ready-to-use therapeutic food (RUTF)?
RUTF is a nutrient-dense paste containing peanuts, milk powder, oil, sugar, and essential vitamins designed to treat severe acute malnutrition in children. It requires no preparation and can be administered at home by caregivers.
How effective is RUTF treatment?
RUTF achieves cure rates of 85-90% when properly administered, according to UNICEF data. Treatment typically lasts 6-8 weeks depending on the child’s nutritional status and response.
Why do so many children still lack access to RUTF?
Major barriers include high costs ($40-200 per treatment course), limited production capacity, supply chain disruptions, and inadequate healthcare infrastructure in affected regions. Geographic remoteness and conflict further compound access challenges.
Addressing the global RUTF treatment gap will require coordinated efforts across multiple sectors, including increased funding for procurement and distribution, expanded local production capacity, and strengthened healthcare systems in affected regions. The success of the past three decades demonstrates that with adequate resources and political commitment, closing this gap is achievable within the next decade.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
